Detalles de la búsqueda
1.
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Drug Resist Updat
; 20: 12-28, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26021435
2.
Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.
Angew Chem Int Ed Engl
; 55(36): 10890-4, 2016 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27466205
3.
Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.
Eur J Med Chem
; 240: 114584, 2022 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35868124
4.
Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
Eur J Med Chem
; 218: 113371, 2021 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794385
5.
From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).
Eur J Med Chem
; 210: 112963, 2021 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33199152
6.
Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.
Eur J Med Chem
; 209: 112901, 2021 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33092905
7.
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
J Med Chem
; 60(11): 4636-4656, 2017 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28482151
8.
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
J Med Chem
; 60(13): 5613-5637, 2017 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28603991
Resultados
1 -
8
de 8
1
Próxima >
>>